Skip to content
10-Q

Quarterly Report

Dova Pharmaceuticals Inc.

0001685071-19-000015

← back to feed
Filed
May 7, 2019 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · May 6, 2019 28.23M sh
Capex Q1 2019 · Mar 31, 2019 $19K
Capex Q1 2019 · Mar 31, 2018 $129K
Operating Cash Flow Q1 2019 · Mar 31, 2019 −$11.94M
Operating Cash Flow Q1 2019 · Mar 31, 2018 −$11.74M
Long Term Debt Q1 2019 · Mar 31, 2019 $11.67M
Long Term Debt Q1 2019 · Dec 31, 2018 $13.94M
Short Term Debt Q1 2019 · Mar 31, 2019 $9.17M
Short Term Debt Q1 2019 · Dec 31, 2018 $6.67M
Cash And Equivalents Q1 2019 · Mar 31, 2019 $92.7M
Cash And Equivalents Q1 2019 · Dec 31, 2018 $104.57M
Stockholders Equity Q1 2019 · Mar 31, 2019 $63.29M
Stockholders Equity Q1 2019 · Dec 31, 2018 $76.36M
Stockholders Equity Q1 2019 · Mar 31, 2018 $125.1M
Stockholders Equity Q1 2019 · Dec 31, 2017 $61.18M
Current Liabilities Q1 2019 · Mar 31, 2019 $22.2M
Current Liabilities Q1 2019 · Dec 31, 2018 $19.5M
Total Liabilities Q1 2019 · Mar 31, 2019 $37.54M
Total Liabilities Q1 2019 · Dec 31, 2018 $35.81M
Current Assets Q1 2019 · Mar 31, 2019 $99.13M
Current Assets Q1 2019 · Dec 31, 2018 $111.81M
Total Assets Q1 2019 · Mar 31, 2019 $100.83M
Total Assets Q1 2019 · Dec 31, 2018 $112.17M
Rd Expense Q1 2019 · Mar 31, 2019 $4.08M
Rd Expense Q1 2019 · Mar 31, 2018 $3.42M
Net Income Q1 2019 · Mar 31, 2019 −$16.38M
Net Income Q1 2019 · Mar 31, 2018 −$13.77M
Operating Income Q1 2019 · Mar 31, 2019 −$16.35M
Operating Income Q1 2019 · Mar 31, 2018 −$13.68M
Revenue Q1 2019 · Mar 31, 2019 $4M
Revenue Q1 2019 · Mar 31, 2018 $0